FDA Drug Recalls

Recalls / Class II

Class IID-096-2013

Product

Nalbuphine HCl Injection, 20 mg/mL, 10 mL Multiple-dose Fliptop Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1467-01

Brand name
Nalbuphine Hydrochloride
Generic name
Nalbuphine Hydrochloride
Active ingredient
Nalbuphine Hydrochloride
Route
Intramuscular, Intravenous, Subcutaneous
NDCs
0409-1463, 0409-1465, 0409-1464, 0409-1467
FDA application
ANDA070914
Affected lot / code info
Lot #: 11-293-DK, Exp 05/01/13

Why it was recalled

Lack of Assurance of Sterility: Complains of a loose crimp applied to the fliptop vial; and a missing stopper and flip cap were received and therefore sterility cannot be assured.

Recalling firm

Firm
Hospira, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
600 N Field Dr Bldg J45, Lake Forest, Illinois 60045

Distribution

Quantity
145,400 vials
Distribution pattern
Nationwide and Puerto Rico.

Timeline

Recall initiated
2012-11-21
FDA classified
2012-12-20
Posted by FDA
2012-12-26
Terminated
2014-06-03
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-096-2013. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Nalbuphine Hydrochloride · FDA Drug Recalls